If the enhanced credits currently available to Affordable Care Act (ACA) Marketplace enrollees are allowed to expire for 2026 ...

The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...

The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...

Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...